EP3698120A1 - Solution et procédé pour faire adhérer des constituants de suspension à un substrat - Google Patents

Solution et procédé pour faire adhérer des constituants de suspension à un substrat

Info

Publication number
EP3698120A1
EP3698120A1 EP18868869.1A EP18868869A EP3698120A1 EP 3698120 A1 EP3698120 A1 EP 3698120A1 EP 18868869 A EP18868869 A EP 18868869A EP 3698120 A1 EP3698120 A1 EP 3698120A1
Authority
EP
European Patent Office
Prior art keywords
sample
solution
attachment
substrate
attachment solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18868869.1A
Other languages
German (de)
English (en)
Other versions
EP3698120A4 (fr
Inventor
Daniel E. CAMPTON
Joshua Nordberg
Ronald C. Seubert
Steve QUARRE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rarecyte Inc
Original Assignee
Rarecyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/787,185 external-priority patent/US10101248B1/en
Application filed by Rarecyte Inc filed Critical Rarecyte Inc
Publication of EP3698120A1 publication Critical patent/EP3698120A1/fr
Publication of EP3698120A4 publication Critical patent/EP3698120A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/2813—Producing thin layers of samples on a substrate, e.g. smearing, spinning-on
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9486—Analgesics, e.g. opiates, aspirine

Definitions

  • This disclosure relates generally to analyzing a suspension and, in particular, to a solution and method for adhering a component of a suspension to a substrate.
  • Figure 1 shows a flowchart of an example method for making an example attachment solution.
  • Figure 2 shows a flowchart of an example method for adhering a sample to a substrate.
  • Figure 3A shows an example sample having been re-suspended in an example attachment solution.
  • Figure 3B shows the example sample mixing with the attach solution to form a re- suspended cytological sample.
  • Figure 3C shows the re-suspended sample being deposited on an example analysis platform.
  • Figure 3D shows the re-suspended sample having been spread on and adhered to the analysis platform.
  • the attachment solution includes an attachment base and a nonsteroidal anti-inflammatory drug.
  • the attachment base may be an alcohol, an acid, an oxidizer, an organohalogen, a ketone, such as acetone, or any combination thereof, such as Carnoy's solution.
  • the attachment solution may also include an anti-coagulant.
  • sample is used to describe a specimen to be analyzed.
  • the specimen may be a suspension, a portion of the suspension, or a component of the suspension.
  • the sample when the suspension is anticoagulated whole blood, the sample may be the anticoagulated whole blood (i.e. a suspension), the buffy coat (i.e. a portion of the suspension), or a circulating tumor cell (i.e. a component of the suspension).
  • the attachment solution may adhere a sample to a substrate.
  • the sample can be a buffy coat of a blood sample and the substrate can be the surface of a microscope slide.
  • the attachment solution includes an attachment base and a nonsteroidal anti-inflammatory drug.
  • the attachment solution may also include water.
  • a buffer may also be included or a buffered solution may be used in place of or in addition to the water.
  • a buffer or a buffer of the buffered solution may include, but is not limited to, ACES, ADA, AMP, AMPD, AMPSO, BES, Bicine, BIS-TRIS, BIS-TRIS propane, CABS, CAPS, CAPSO, CHES, DIPSO, EDTA, HEPPS (EPPS), Gly-Gly, HEPBS, HEPES, MES, MOPS, MOPSO, PIPES, POPSO, potassium phosphate, sodium phosphate (monobasic and/or dibasic), TAPS, TAPSO, TES, Tricine, tris, Trizma ® , and combinations thereof.
  • the pH of the buffer or buffer solution may range from 5 to 12.
  • the attachment solution includes a salt, such as that in a saline solution, where the attachment solution remains hypotonic relative to the sample, as an isotonic or hypertonic attachment solution may cause the sample to crack while drying or curing.
  • the attachment solution does not include a salt, such as that included in a saline solution, as the salt may cause the sample to crack while drying or curing.
  • the attachment base may include an alcohol, such as ethanol, methanol, propanol, isopropanol, butanol, and an acid, an oxidizer, an organohalogen, a ketone, such as acetone, or any combination thereof, such as Carnoy's solution.
  • the attachment base may be capable of fixing sample components, such as cells, without cross-linking other sample components, such as proteins. Preventing cross-linking of the other sample components, such as proteins, may avoid an additional processing step, such as antigen retrieval. In other words, fixing sample components to a substrate with the attachment base eliminates the process of antigen retrieval.
  • the attachment base may also have a fast (i.e. less than one hour) cure time.
  • the attachment base may have a final concentration, such as when the attachment solution and the sample have been mixed, of 60-70% by volume, and more specifically 63-68% by volume. Having a concentration of the attachment base outside the desired range may affect the sample or a portion thereof, such as by lysis, clumping, inability to adhere to the substrate, or the like.
  • the final concentration of the attachment base may be determined by a measured property of the sample to be adhered including, but not limited to, sample volume, packed cell volume, hematocrit level, blood type, sample type (i.e. blood, urine, buffy coat, single cell, etc.), or the like.
  • the nonsteroidal anti-inflammatory drug may be, but is not limited to, acetylsalicylic acid, celecoxib (Celebrex), diclofenac (Voltaren), diflunisal (Dolobid), etodolac (Lodine), ibuprofen (Motrin), indomethacin (Indocin), ketoprofen (Orudis), ketorolac (Toradol), nabumetone (Relafen), naproxen (Aleve, Naprosyn), oxaprozin (Daypro), piroxicam (Feldene), salsalate (Amigesic), sulindac (Clinoril), tolmetin (Tolectin), or the like.
  • the nonsteroidal anti-inflammatory drug may act as an antithrombotic (i.e. reducing blood clotting, such as by reducing the blood clotting function of various blood components).
  • the nonsteroidal anti-inflammatory drug may have a final concentration of 100-1000 ug/mL.
  • the attachment solution may also include an anti-coagulant which may be, but is not limited to, heparin, heparin sodium, heparin/dextrose, ethylene-diamine-tetra-acetic acid, dalteparin sodium, argatroban, bivalirudin, lepirudin, or the like.
  • the anti-coagulant prevents coagulation (i.e. clumping, clotting or solidification) of the sample.
  • the anti-coagulant may have a final concentration of 10-1000 ug/mL.
  • the attachment solution may also include a biological polymer to increase the adhesion between the sample and the substrate.
  • the biological polymer may include, but is not limited to, biomimetic adhesive polymers (such as polyphenolic protein from marine life; 3,4- dihydroxyphenylalanine), fibrin glue, gelatin-resorcinol-formaldehyde, poly-L-lysine, poly-D- lysine, or the like.
  • Heparin 2000 ⁇ g/mL Prepared by dissolving 20mg of heparin sodium salt (Sign
  • BD Cell-Tak BD Cell-Tak® Cell and Tissue Adhesive (BD 354241) - approximately 1500 ⁇ g/mL stock concentration
  • Cell-Tak Buffer 5X Prepared by dissolving 21g sodium bicarbonate (NaHC0 3 ) into
  • Cell-Tak Buffer IX Prepared by dissolving 4.2g sodium bicarbonate (NaHC0 3 ) into 500mL of water and adding 2.5 mL 1M hydrochloric acid (HC1)
  • Figure 2 shows an example method for adhering a sample to a substrate.
  • a sample is obtained.
  • the sample may be withdrawn directly from a subject or the sample may undergo enrichment and/or isolation from the suspension.
  • the sample may be enriched by any appropriate enrichment process including, but not limited to, sequential density fractionation, magnetic-activated cell sorting, fluorescence-activated cell sorting, differential lysis, depletion filters, or the like.
  • Sequential density fractionation is a process by which a suspension is divided into fractions or a fraction of a suspension is divided into sub- fractions by a step-wise or sequential process, such that each step or sequence results in the collection or separation of a different fraction or sub-fraction from the preceding and successive steps or sequences.
  • the sample may be obtained from other suspension components by selecting the sample with a device for picking, such as a cell picker, a pipet, a syringe, or the like.
  • the sample 304 is re-suspended in an attachment solution 306 in a vessel 302, as shown in Figure 3A.
  • the attachment solution may be added to or mixed with the sample.
  • the re-suspended sample 308, which includes at least a portion of the attachment solution, as shown in Figure 3B, is dispensed onto or into an analysis platform 310 by a dispenser, such as a pipet or repeating pipet, and spread across the analysis platform.
  • a dispenser such as a pipet or repeating pipet
  • the sample 308 is spread across the analysis platform 310 by a spreader 312, such as a squeegee, a pipet tip, a blade, a two-piece spreader including a blade and a base.
  • the sample 308 may be spread across the analysis platform 310 by centrifuging, wetting, or nutating the analysis platform 310.
  • the re-suspended sample 308 is cured, as shown in Figure 3D, to adhere the re-suspended sample 308 to the analysis platform 310.
  • the re-suspended sample 308 may be dispensed onto the analysis platform 310 and cured without being spread across the analysis platform 310. Curing may occur in air, such as at room temperature; in an environmentally-controlled chamber, such as at 37°C; or the like.
  • the sample may undergo an additional fixation step, such as in formalin or any appropriate fixative, after the curing step has been completed.
  • the attachment solution may be compatible with any appropriate analysis method or technique, though more specifically extracellular and intracellular analysis including immunofluorescent labeling and imaging; intracellular protein labeling; chromogenic staining; molecular analysis; genomic analysis or nucleic acid analysis, including, but not limited to, genomic sequencing, DNA arrays, expression arrays, protein arrays, and DNA hybridization arrays; in situ hybridization (“ISH”— a tool for analyzing DNA and/or RNA, such as gene copy number changes); polymerase chain reaction (“PCR”); reverse transcription PCR; or branched DNA (“bDNA”— a tool for analyzing DNA and/or RNA, such as mRNA expression levels) analysis.
  • ISH in situ hybridization
  • PCR polymerase chain reaction
  • bDNA branched DNA
  • intracellular proteins which may be labeled include, but are not limited to, cytokeratin ("CK"), actin, Arp2/3, coronin, dystrophin, FtsZ, myosin, spectrin, tubulin, collagen, cathepsin D, ALDH, PBGD, Aktl, Akt2, c-myc, caspases, survivin, p27 p , FOXC2, BRAF, Phospho-Aktl and 2, Phospho-Erkl/2, Erkl/2, P38 MAPK, Vimentin, ER, PgR, PI3K, pFAK, KRAS, ALKH1, Twistl, Snaill, ZEB 1, Fibronectin, Slug, Ki-67, M30, MAGEA3, phosphorylated receptor kinases, modified histones, chromatin-associated proteins, and MAGE.
  • CK cytokeratin
  • actin actin
  • Arp2/3, coronin coronin
  • the analysis platform 310 may be a microscope slide, a positively charged microscope slide, a coated microscope slide, a porous slide, a micro-well slide, a well plate, a coverslip, a cell microarray, or the like.
  • the analysis platform 310 may be any appropriate material, including, but not limited to, glass, plastic, ceramic, metal, or the like.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne un procédé et une solution de fixation pour faire adhérer un échantillon cytologique ou histologique, tel qu'une couche leuco-plaquettaire, à un substrat, tel qu'une lame de microscope. La solution de fixation comprend une base de fixation, un anticoagulant, et un médicament anti-inflammatoire non stéroïdien. La base de fixation peut être un alcool, un acide, un oxydant, un organo-halogène, une cétone, ou n'importe quelle combinaison de ceux-ci. Une fois qu'un échantillon est obtenu, l'échantillon peut être remis en suspension dans la solution de fixation ou la solution de fixation peut être ajoutée à l'échantillon. L'échantillon peut ensuite être distribué sur une plate-forme d'analyse sous la forme d'une ou de plusieurs gouttelettes et durci.
EP18868869.1A 2017-10-18 2018-10-17 Solution et procédé pour faire adhérer des constituants de suspension à un substrat Withdrawn EP3698120A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/787,185 US10101248B1 (en) 2015-12-02 2017-10-18 Solution and method for adhering suspension components to a substrate
PCT/US2018/056170 WO2019079363A1 (fr) 2017-10-18 2018-10-17 Solution et procédé pour faire adhérer des constituants de suspension à un substrat

Publications (2)

Publication Number Publication Date
EP3698120A1 true EP3698120A1 (fr) 2020-08-26
EP3698120A4 EP3698120A4 (fr) 2021-07-21

Family

ID=66174624

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18868869.1A Withdrawn EP3698120A4 (fr) 2017-10-18 2018-10-17 Solution et procédé pour faire adhérer des constituants de suspension à un substrat

Country Status (4)

Country Link
EP (1) EP3698120A4 (fr)
JP (1) JP2021500553A (fr)
CN (1) CN111226105A (fr)
WO (1) WO2019079363A1 (fr)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2286191A1 (fr) * 1974-09-30 1976-04-23 Pasteur Institut Principes nutritifs a base de proteines, compositions alimentaires contenant de tels principes nutritifs et leur procede d'obtention
US5256571A (en) * 1991-05-01 1993-10-26 Cytyc Corporation Cell preservative solution
JP3067849B2 (ja) * 1991-07-29 2000-07-24 シスメックス株式会社 白血球分類計数用試料調製方法
AU2001251114A1 (en) * 2000-03-28 2001-10-08 Board Of Regents, The University Of Texas System Enhancing contrast in biological imaging
WO2002026114A2 (fr) * 2000-09-27 2002-04-04 Bitensky Mark W Jeux d'echantillons de diagnostic cellulaire, methodes d'utilisation et procedes de fabrication
CA2618710A1 (fr) * 2005-08-11 2007-02-22 David Edwards Procedes et compositions pour formes cellulaires sechees
JP5559096B2 (ja) * 2011-05-10 2014-07-23 株式会社堀場製作所 血球計数用試薬、及び血液検査方法
US10101247B2 (en) * 2013-07-19 2018-10-16 Rarecyte, Inc. Solution and method for adhering suspension components to a substrate
WO2016089966A1 (fr) * 2014-12-02 2016-06-09 Rarecyte, Inc. Solution et procédé pour faire adhérer des constituants de suspension à un substrat

Also Published As

Publication number Publication date
JP2021500553A (ja) 2021-01-07
WO2019079363A1 (fr) 2019-04-25
EP3698120A4 (fr) 2021-07-21
CN111226105A (zh) 2020-06-02

Similar Documents

Publication Publication Date Title
US20230393071A1 (en) Methods and compositions for partitioning a biological sample
US20240253036A1 (en) Fluid delivery methods
US20230034039A1 (en) Methods of preserving a biological sample
US10002316B2 (en) Spatially addressable molecular barcoding
CN107407691B (zh) 用于单细胞中核酸靶标的分子条码化的装置和系统
WO2023150098A1 (fr) Procédés, kits, compositions et systèmes d'analyse spatiale
JP2022088380A (ja) コンビナトリアルバーコーディングのための方法および組成物
CN113767176A (zh) 成像系统硬件
WO2016196229A1 (fr) Méthodes de quantification d'arn
CN101354327B (zh) 测量糖化血色素的系统和方法
WO2024086776A1 (fr) Réseaux de microbilles hybrides
US10101248B1 (en) Solution and method for adhering suspension components to a substrate
US10101247B2 (en) Solution and method for adhering suspension components to a substrate
EP4090464A1 (fr) Dispositif microfluidique et procédé de synthèse automatisée par division de groupe
US20220280941A1 (en) Systems and methods for generating droplets and performing digital analyses
JP6970665B2 (ja) 細胞外小胞回収方法及び細胞外小胞用容器
EP3698120A1 (fr) Solution et procédé pour faire adhérer des constituants de suspension à un substrat
Burgemeister Nucleic acids extraction from laser microdissected FFPE tissue sections
WO2016089966A1 (fr) Solution et procédé pour faire adhérer des constituants de suspension à un substrat
US20150024427A1 (en) Solution and method for adhering suspension components to a substrate
AU2018306481B2 (en) Method for immobilising biological samples for analytical and diagnostic purposes
US12000842B2 (en) Systems and methods for generating droplets and performing digital analyses
US20240369572A1 (en) Systems and methods for generating droplets and performing digital analyses
US20230184663A1 (en) Devices, systems, and methods for debubbling
Subramanian Dissecting gene expression of single cells with reduced perturbation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200408

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20210621

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 1/28 20060101AFI20210615BHEP

Ipc: G01N 1/30 20060101ALI20210615BHEP

Ipc: G02B 21/34 20060101ALI20210615BHEP

Ipc: G01N 33/94 20060101ALI20210615BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20220114